said (P = .0053 versus the control diet of 2-4 g sodium/day).
doesn't come right out and say it, but what he's getting at is that religion is fine among leaders as long as they don't take it too seriously.
R-PE was thiolated by Traut's Reagent (2-Iminothiolane or 2-IT) (Sigma-Aldrich) for 1.5 hr at RT, while the antibody was attached to a heterobifunctional linker
called SPDP (A -succinimidyl 3-(2-pyridyldithio)-propionate) (Uptima, Montiucon, Cedex, France) in PBS.
does himself no credit in seeking to revive it now.
Three receive close scrutiny in Linker
's first chapter--George Weigel, biographer of Pope John Paul II and expositor of a take on Catholic "just war" theory tailored to support Bush's foreign policy; Michael Novak, the Catholic radical turned outspoken champion of "democratic capitalism"; and Linker
's bete noire and former boss (for whom he insists he has no ill will), Fr.
From 2001 to 2005, Linker
worked side by side with Neuhaus as an editor at the latter's monthly journal, First Things, and presumably shared his boss's enthusiasm for mixing prophetic religion and radical politics.
And when Linker
informs us that these men have achieved their victory by keeping a "low public profile" so as to "influence politics and policy quietly, behind the scenes," our expectations are understandably raised.
At the same time, says Linker
, he and his collaborators plan to use the STEREO images to hone the model they have developed.
Survivors include her husband; a daughter, Lori Linker
of Portland; three sons, Karry of Deerfield, N.H., Jason of Oregon City and Brad of Springfield; a brother, Raymond Settles of Las Vegas; three sisters, Eva Kanode of Henry, Va., Stella Barley of Veneta and Ruth Settles of California City, Calif.; and two grandchildren.
We have also found that the emission spectrum of a microbead with a seven-methylene linker
between the fluorescein and the bead surface (bead7) provides the best match with the spectra from biological cells.
downplays talk of a depressed newspaper advertising market in 2002.
"We are excited about combining our expertise in the areas of monoclonal antibodies, linker
technology and potent drugs for the development of novel therapies for cancer."